spironolactone - HEALTHIES
TCTMD: SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF The trial enrolled just half of its planned patients, leaving spironolactone’s role in HFpEF and HFmrEF still up in the air. SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF Spironolactone use among young women and girls has been growing since 2000 for acne and other androgen-related conditions. Although established for cardiovascular indications, spironolactone is not ...
Understanding the Context
Medical Dialogues: Spironolactone may not reduce CV mortality and hospitalizations in patients with HFpEF or HFmrEF: SPIRIT-HF Trial Spironolactone showed no significant benefit in reducing the composite of cardiovascular mortality and heart failure hospitalizations, recording 12.7 events per 100 patient-years versus 10.8 for the ... Spironolactone may not reduce CV mortality and hospitalizations in patients with HFpEF or HFmrEF: SPIRIT-HF Trial Please provide your email address to receive an email when new articles are posted on . While the level of evidence was generally low, spironolactone was not associated with statistically significant ... Medical Xpress: Amiloride found to be as effective as spironolactone in managing resistant hypertension Yonsei University College of Medicine-led research has shown amiloride is as effective as spironolactone in reducing systolic blood pressure (SBP) over 12 weeks in patients with resistant hypertension ...
Image Gallery
Key Insights
Amiloride found to be as effective as spironolactone in managing resistant hypertension Teen Vogue: Spironolactone Might Be an Alternative to Taking Antibiotics for Acne Science Daily: Spironolactone did not reduce primary outcome, did reduce hospitalizations for heart failure Adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or ... Spironolactone did not reduce primary outcome, did reduce hospitalizations for heart failure